Borroto-Escuela Dasiel O, Fuxe Kjell
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Biomolecular Science, Section of Physiology, University of Urbino, Urbino, Italy.
Front Endocrinol (Lausanne). 2019 Aug 20;10:574. doi: 10.3389/fendo.2019.00574. eCollection 2019.
Based on the work in the Central Nervous System with discoveries of allosteric receptor-receptor interactions in homo- and heteroreceptor complexes representing a major integrative mechanism in synapses and extrasynaptic regions, it is proposed that a similar mechanism may exist in the immunological synapses. We discuss a putative additional molecular mechanism for the ability of the inhibitory T cell signaling proteins CTLA-4 and PD-1 and the adenosine A2AR to diminish T cell activation leading to enhancement of cancer development. We suggest that in the same immunological synapse involving T cells and antigen presenting cells multiple heteroreceptor complexes may participate and be in balance with each other. Their composition can vary between functional states and among different types of T cells. The T cell receptor (TCR) and its accelerators, strongly enhancing T cell activation, can be under inhibitory control by T cell signaling proteins CTLA4 and PD-1 and also the adenosine A2AR through inhibitory allosteric receptor-receptor interactions in different types of heteroreceptor complexes. As a result, inhibitory tumor induced immunosuppression can develop due to a dominance of the inhibitory signaling causing a brake on the TCR and/or its accelerator and the cancer immunotherapy becomes blocked.
基于在中枢神经系统的研究工作,发现同型和异型受体复合物中的变构受体-受体相互作用是突触和突触外区域的主要整合机制,因此提出免疫突触中可能存在类似机制。我们讨论了一种假定的额外分子机制,涉及抑制性T细胞信号蛋白CTLA-4和PD-1以及腺苷A2AR,它们能够减弱T细胞活化,从而导致癌症发展增强。我们认为,在涉及T细胞和抗原呈递细胞的同一免疫突触中,多个异型受体复合物可能参与其中并相互平衡。它们的组成在功能状态之间以及不同类型的T细胞之间可能有所不同。T细胞受体(TCR)及其促进剂能强烈增强T细胞活化,但可通过不同类型异型受体复合物中的抑制性变构受体-受体相互作用,受到T细胞信号蛋白CTLA4和PD-1以及腺苷A2AR的抑制性控制。结果,由于抑制性信号占主导,导致TCR和/或其促进剂受到抑制,从而产生抑制性肿瘤诱导的免疫抑制,癌症免疫疗法也因此受阻。